Results 21 to 30 of about 4,730,453 (227)

Erythropoietin therapy in a case of neonatal anemia after exposure to natalizumab throughout pregnancy

Italian Journal of Pediatrics, 2021
Background Natalizumab is a monoclonal antibody approved for the treatment of patients with relapsing-remitting multiple sclerosis. According to the current clinical recommendations, its use during pregnancy should be carefully evaluated only in women ...
Elisabetta Godano, Fabio Barra, Alessandra Allodi, Antonella Ferraiolo, Alice Laroni, Giovanni Novi, Giovanni Luigi Mancardi, Claudio Gustavino, Cesare Arioni   +8 more
doaj   +1 more source

Genomic regions associated with multiple sclerosis are active in B cells. [PDF]

, 2012
More than 50 genomic regions have now been shown to influence the risk of multiple sclerosis (MS). However, the mechanisms of action, and the cell types in which these associated variants act at the molecular level remain largely unknown.
Giulio Disanto, Berlanga-Taylor Antonio J., Giulio Disanto (125817), Gavin Giovannoni, Sandve, GK, Berlanga-Taylor, AJ, Antonio J. Berlanga-Taylor (179950), Morahan Julia M., Geir Kjetil Sandve (31750), Julia M Morahan, Dobson, R, Antonio J Berlanga-Taylor, Dobson Ruth, Julia M. Morahan, Gavin Giovannoni (125820), Antonio J. Berlanga-taylor, Sreeram V. Ramagopalan, Giovannoni Gavin, Ramagopalan Sreeram V., Morahan, JM, Ramagopalan, SV, Sandve Geir Kjetil, Geir Kjetil S, Ruth Dobson, Ruth Dobson (179953), Sreeram V. Ramagopalan (125826), Ramagopalan, Sreeram, Sreeram V Ramagopalan, Disanto Giulio, Julia M. Morahan (179952), Giovannoni, G, Geir Kjetil Sandve, Disanto, G   +32 more
core   +1 more source

Quantification of cerebral tissue volumes in multiple sclerosis: global and regional analysis [PDF]

, 2006
Brain atrophy has been reported in multiple sclerosis (MS). We addressed the question of GM and WM tissue loss in a large population of 597 patients with multiple sclerosis (MS) compared with 104 control subjects using a fully automated, operator ...
Prinster, Anna
core   +1 more source

Use and cost of disease-modifying therapies by Sonya Slifka Study participants: has anything really changed since 2000 and 2009?

Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2019
Background Disease-modifying therapies benefit individuals with relapsing forms of multiple sclerosis, but their utility remains unclear for those without relapses.
Sarah L Minden, R Philip Kinkel, Helene T Machado, Jonathan S Levin, Meredith B Rosenthal, Lisa I Iezzoni   +5 more
doaj   +1 more source

Different cognitive profiles of Brazilian patients with relapsing-remitting and primary progressive multiple sclerosis

Arquivos de Neuro-Psiquiatria, 2011
Cognitive impairment is a symptom of multiple sclerosis (MS). Different clinical forms of multiple sclerosis have different cognitive profiles, according to findings of previous studies which used extensive batteries of neuropsychological tests ...
Dóra-Neide Rodrigues, Renata Alves Paes, Claudia Cristina Ferreira Vasconcelos, Jesus Landeira-Fernandez, Maria Papais Alvarenga   +4 more
doaj   +1 more source

Onset of secondary progressive multiple sclerosis is not influenced by current relapsing multiple sclerosis therapies

Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2018
Background Disease-modifying therapies are thought to reduce the conversion rate to secondary progressive multiple sclerosis. Objective To explore the rate, chronology, and contributing factors of conversion to the progressive phase in treated relapsing ...
Francisco Coret, Francisco C Pérez-Miralles, Francisco Gascón, Carmen Alcalá, Arantxa Navarré, Ana Bernad, Isabel Boscá, Matilde Escutia, Sara Gil-Perotin, Bonaventura Casanova   +9 more
doaj   +1 more source

Cognition and cognitive rehabilitation in adult and juvenile patients with multiple sclerosis [PDF]

, 2015
: Multiple sclerosis (MS) is accompanied by cognitive deficits in half of adult patients and in one third of children. These deficits have a serious impact on daily functioning of patients and may influence the ability to achieve educational goals and ...
Hubacher, Martina
core   +1 more source

Faster progression to multiple sclerosis disability is linked to neuronal pathways associated with neurodegeneration: An ethnicity study.

PLoS ONE, 2023
Although the causes of multiple sclerosis are largely unknown, genetic and environmental components play an important role. Geographic distribution, varying with latitude, reflects both genetic and environmental influences.
Gil Harari, Michael Gurevich, Mark Dolev, Rina Zilkha Falb, Anat Achiron   +4 more
doaj   +1 more source

Evaluation of cognitive assessment and cognitive intervention for people with multiple sclerosis [PDF]

, 2002
Objectives: Cognitive problems in multiple sclerosis are common but any possible benefits of treatment remain uncertain. The aim of the study was to evaluate the benefits of providing a psychology service, including cognitive assessment and intervention,
Weyman, N., Blumhardt, L. D., Blumhardt, L.D., Harding, J., Lincoln, N. B., Dent, A., Nicholl, C., Lincoln, N.B., Playford, E.D., Playford, E. Diane   +9 more
core   +1 more source

Impact of treatment with dimethyl fumarate on sleep quality in patients with relapsing-remitting multiple sclerosis: A multicentre Italian wearable tracker study

Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2023
Background Sleep disorders are common in patients with multiple sclerosis and have a bidirectional interplay with fatigue and depression. Objective To evaluate the effect of treatment with oral dimethyl fumarate on the quality of sleep in relapsing ...
Giancarlo Comi, Letizia Leocani, Luigi Ferini-Strambi, Marta Radaelli, Gloria D Costa, Roberta Lanzillo, Giacomo Lus, Valentina Bianchi, Sebastiano Traccis, Fioravante Capone, Luigi ME Grimaldi, Giuseppe Salemi, Alessandra Cardillo, Valentina Zipoli,   +14 more
doaj   +1 more source